SMURF2 and polycystic ovary syndrome: Due to the increase in the number of GV oocytes in women with PCOS, it is suggested that the addition of recombinant P-Smad2/3 proteins and inhibitor of SMURF2 may be effective in increasing the number of MII oocytes and fertility outcomes in these women and even treatment of human infertility using immature oocytes collected from natural cycles.